PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT02819726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis (RA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A randomised, double blind, parallel group, multicentre study yo compare the pharmacokinetics, pharmacokinetics, safety and efficacy of SAIT101 versus MabThera® versus Rituxan® in patients with rheumatoid arthritis.
Study identification
- NCT ID
- NCT02819726
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 294 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 11, 2016 (Actual)
- Primary completion
- Apr 30, 2018 (Actual)
- Completion
- Nov 7, 2018 (Actual)
- Last update posted
- Feb 17, 2020
2016 – 2018
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anniston | Alabama | 36207 | — |
| Research Site | El Cajon | California | 92020 | — |
| Research Site | La Mesa | California | 91942 | — |
| Research Site | Lakewood | California | 90712 | — |
| Research Site-1 | Los Angeles | California | 90017 | — |
| Research Site-2 | Los Angeles | California | 90017 | — |
| Research Site | San Leandro | California | 94578 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Tampa | Florida | 33613 | — |
| Research Site | Boise | Idaho | 83642 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Lansing | Michigan | 48917 | — |
| Research Site | Waco | Texas | 76710 | — |
| Research Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02819726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2020 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02819726 live on ClinicalTrials.gov.